Royalty Pharma (RPRX) Common Equity (2019 - 2026)

Royalty Pharma has reported Common Equity for 8 years, with the latest figure at $9.9 billion in Q1 2026.

• Quarterly Common Equity rose 1.63% year-over-year to $9.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.9 billion (up 1.63% YoY) and the FY2025 annual result came in at $9.7 billion, down 6.07% from the prior year.
• Common Equity grew to $9.9 billion in Q1 2026 per RPRX's latest filing, from $9.7 billion in the prior quarter.
• Over five years, Common Equity peaked at $10.4 billion in Q3 2022 and troughed at $9.5 billion in Q2 2025.
• A 5-year average of $9.9 billion and a median of $9.8 billion in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2024: Common Equity decreased 7.98% in 2023, then advanced 7.03% in 2024.
• Over 5 years, Common Equity stood at $9.5 billion in 2022, then climbed by 5.87% to $10.1 billion in 2023, then climbed by 2.56% to $10.3 billion in 2024, then slipped by 6.07% to $9.7 billion in 2025, then rose by 2.28% to $9.9 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $9.9 billion, $9.7 billion, and $9.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.